This approach is further supported by statistics from The Cancer Genome Atlas, which demonstrates that breast tumours with CCND1 amplification concomitantly increase CDK4/6 activity, and exhibit much lower expression of the MHC class I components HLAA, HLA-B, and HLA-C versus tumours without amplification [64,74,75]. This evidence concerns the gene CDK4 and neoplasm.